Kelonia Therapeutics' KLN-1010 has shown promising early results in a phase 1 trial for relapsed or refractory multiple ...

Shayla Bergmann, MD, explains that recombinant von Willebrand factor is both safe and highly effective in controlling ...

Continuous glucose monitoring (CGM) is underutilized in non-insulin-treated type 2 diabetes (T2D) despite evidence of ...

Clinicians and health system leaders met in Portland, Oregon, on October 21, 2025, to discuss the evolving options for ...

Azacitidine-venetoclax showed superior event-free survival and overall response rates compared to traditional induction ...

School reopenings after COVID-19 closures significantly improved children's mental health, reducing diagnoses of depression, ...

Erika Hamilton, MD, reports early trial data showing DB-1305/BNT325, a TROP2-targeted ADC, produced encouraging responses in ...

Panelists discuss how noninvasive risk assessments enable early detection and targeted management of fibrosis in MASH ...

Ryan Haumschild, PharmD, MS, MBA, introduces the faculty and sets the agenda to explore disease background, novel therapies, ...

ICHRAs may help employers and employees manage rising premiums and the loss of extended tax credits, according to expert ...

The symposium will present new research, including significant trials like HER2CLIMB-05, LidERA, and DESTINY-Breast11, through various sessions. SABCS 2025 will spotlight new advances in breast cancer ...

In interviews with The American Journal of Managed Care®, Jennifer Graff, PharmD, of Innov8 Health Policy; Joey Mattingly, PharmD, MBA, PhD, of the University of Utah College of Pharmacy; and Brian ...